Sucampo Pharma (SCMP) Tops Q3 EPS by 2c, Guidance Beats

Sucampo Pharma (NASDAQ: SCMP) reported Q3 EPS of $0.28, $0.02 better than the analyst estimate of $0.26. Revenue for the quarter came in at $57.9 million versus the consensus estimate of $51.46 million.

GUIDANCE:

Sucampo Pharma sees FY2016 EPS of $1.20-$1.25, versus the consensus of $1.04. Sucampo Pharma sees FY2016 revenue of $220-225 million, versus the consensus of $205.7 million.

For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• UBS Reiterates Neutral Rating on Pilgrim's Pride (PPC) on 'Challenging' Near-Term Fundamentals
• AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c